The intracellular bioavailability of lead (Pb) at low dosage levels in major target organs such as the kidney and brain appears to be largely determined by complexation with a group of low molecular weight proteins. These proteins are rich in aspartic and glutamic dicarboxyl amino acids. The proteins are chemically similar but not identical across all species examined to date and the brain protein appears to be different from that found in the kidney. These proteins possess dissociation constant values for Pb on the order of 10-M and appear to normally bind zinc. In rats, these proteins attenuate the Pb inhibition of the heme pathway enzyme 6-aminolevulinic acid dehydratase by a mechanism involving both Pb chelation and zinc donation to this highly Pbsensitive zinc-dependent enzyme. Other studies in rats have shown that the kidney protein facilitates the intranuclear movement of Pb in vitro followed by chromatin binding, suggesting that this protein may be involved in alterations of the pathognomonic Pb intranuclear inclusion bodies in renal gene expression associated with the mitogenic effects of Pb in the kidney.
All models for predicting blood lead values from soil or dust exposures require the movement of lead (Pb) (9, 10) , and research from this laboratory has shown that PbBPs from the rat are capable of both attenuating the effects of Pb on 6-aminolevulinic acid dehydratase (6-ALAD) (11) (12) (13) and mediating the intranuclear movement and chromatin binding (14, 15) of Pb in target cell nuclei from the kidney. These latter effects appear to be quite important in regulating alterations in renal gene expression patterns (16, 17) and possibly Pb-induced renal cancer (18) . PbBPs may also be involved in the formation of Pb-containing intranuclear inclusion bodies in target tissues (19) (20) (21) (22) (23) , as they appear to undergo aggregation after addition of Pb in vitro (24) .
The following discussion reviews the literature on these molecules and examines how they influence individual susceptibility to Pb toxicity in humans and other species.
Lead-Binding Proteins Rats
Kidney. Studies by Oskarsson et al. (4) demonstrated that the rat kidney possessed several low molecular weight protein peaks from rat kidney cytosol. One of these proteins had an estimated molecular mass of 63,000 daltons, which may be a tetramer of the lower molecular weight peak, and showed stable binding of 203Pb on sodium dodecyl sulfate (SDS) gels, indicating a high degree of stability. Subsequent studies (11) (12) (13) (18) (19) (20) (21) (22) (23) . These inclusions (20, (22) (23) Other Species Preliminary studies in monkeys (26) showed that this species has kidney and brain PbBPs proteins with chromatographic characteristics similar to those of humans. The major bands on the gels were enriched in glutamic and aspartic amino acids, but the exact identity of these proteins is currently unknown. Studies on the PbBP from catfish liver (27) also showed similar highly anionic characteristics and the capacity to attenuate the direct inhibitory effects of Pb on 6-ALAD (28 
